Multiple Sclerosis Drugs Market Size to Reach US$31.3 Billion by 2028 | Present a CAGR of 3.7% (2023-2028)
Rising approvals for intramuscular injections are therefore fueling the growth of the multiple sclerosis drug market.
HYDERABAD, TELANGANA, INDIA, Nov. 17, 2022 /EINPresswire.com/ — IndustryARC in its latest report predicts the multiple sclerosis drugs market size to reach $31.3 billion by 2028, with a CAGR of 3.7% over the forecast period 2023-2028. Treatment for multiple sclerosis may involve immunosuppressants, immunomodulators, and monoclonal antibodies. Interferons are disease-modifying drugs that help reduce relapses in people with multiple sclerosis. According to the National Multiple Sclerosis Society, more than 2.8 million people live with multiple sclerosis worldwide. Growing corporate focus on in-development products for multiple sclerosis is expected to drive the multiple sclerosis drug market. The report offers a comprehensive analysis of the market, its main segments, growth factors, trends, drivers and challengers, key players and more.
Click here to browse the full summary of the report:
Key points to remember:
This IndustryARC report on the Multiple Sclerosis Drugs Market highlights the following areas –
1. Geographically, North America (Multiple Sclerosis Drugs Market Share) had the highest revenue share in 2022. It is poised to dominate the market during 2023-2028 due to the increasing prevalence of multiple sclerosis involving immunomodulators in the North American region.
2. The growth of multiple sclerosis drugs market is driven by huge funding from major pharmaceutical companies in the drug development procedure and the rise of interferon treatment of multiple sclerosis. However, soaring drug prices are one of the major factors hampering the growth of the multiple sclerosis drugs market.
3. Multiple Sclerosis Drugs Market A detailed analysis of the strengths, weaknesses and opportunities of key players operating in the market would be provided in the Multiple Sclerosis Drugs Market report.
Want to know more about relevant information? Click here:
Multiple Sclerosis Drugs Market Segment Analysis – By Drug Class: Immunomodulators segment held the largest share of multiple sclerosis drugs market in 2022. This growth is fueled by the growing application of immunomodulators for the treatment of multiple sclerosis and its related symptoms. Interferon beta and glatiramer acetate (GA) were the first immunomodulators certified for the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes.
Multiple Sclerosis Drugs Market Segment Analysis – By Administration Route: Injections segment is sub-segmented into intramuscular, subcutaneous and intravenous. The increasing use of intravenous (IV) infusions like OCREVUS to treat relapsing or primary progressive forms of multiple sclerosis is further propelling the growth of this segment.
Multiple Sclerosis Drugs Market Segment Analysis – By Geography: North America (Multiple Sclerosis Drugs Market) led the Multiple Sclerosis Drugs Market with 40% market share global in 2022. Growth is driven by the existence of key players in the North America Region. The approval by the regulatory authorities is further propelling the growth of the Multiple Sclerosis Drugs industry, thereby contributing to the outlook for the Multiple Sclerosis Drugs industry, in the North American region.
Top 5 Multiple Sclerosis Drugs Industry Players are –
1. Bayer AG
2.Teva Pharmaceutical Industries Ltd.
3. Novartis AG
4. Sanofi Inc.
5. F. Hoffmann-La Roche Ltd.
Click the following link to purchase the Multiple Sclerosis Drugs Market Report:
Why choose IndustryARC?
IndustryARC is one of the world’s leading market research and consulting companies. It produces over 500 unique market reports every year. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your favorite market report from the website, but also get personalized support on specific reports.
A. Primary progressive multiple sclerosis market
B. Interferon Market
Mr Venkat Reddy
Email: [email protected]
USA: (+1) 970-236-3677, (+1) 815-656-4596
IND: (+91) 40-485-49062